Trinity Biotech plc (TRIB): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo dinámico del diagnóstico médico, Trinity Biotech Plc (TRIB) surge como una fuerza pionera, transformando la atención médica a través de soluciones tecnológicas innovadoras. Al mapear estratégicamente su modelo de negocio en asociaciones clave, investigación de vanguardia y diagnósticos impulsados ​​por la precisión, la compañía está a la vanguardia de la revolucionar las metodologías de pruebas clínicas. Su enfoque integral combina perfectamente la biotecnología avanzada, las ideas del mercado global y un compromiso implacable de ofrecer herramientas de diagnóstico de alta precisión que capacitan a los profesionales de la salud en todo el mundo.

Trinity Biotech Plc (Trib) - Modelo de negocio: asociaciones clave

Colaboración estratégica con laboratorios de diagnóstico médico

Trinity Biotech mantiene asociaciones estratégicas con los siguientes laboratorios de diagnóstico:

Socio de laboratorio	Enfoque de colaboración	Región geográfica
Diagnóstico de misiones	Prueba de diagnóstico clínico	Estados Unidos
Laboratorios médicos de Mayo	Prueba de enfermedades infecciosas especializadas	América del norte
Atención médica sonora	Desarrollo de diagnóstico molecular	Australia/Global

Asociaciones de investigación con instituciones académicas y clínicas

Trinity Biotech colabora con centros de investigación académicos:

• Harvard Medical School - Investigación de enfermedades infecciosas
• Universidad Johns Hopkins - Diagnóstico molecular
• University College Dublin - Innovación de biotecnología

Acuerdos de distribución con proveedores de atención médica global

Distribuidor	Líneas de productos	Volumen de distribución anual
Salud cardinal	Analizadores de química clínica	$ 12.5 millones
Henry Schein Medical	Kits de diagnóstico de enfermedades infecciosas	$ 8.3 millones
Industrias Medline	Equipo de prueba de punto de atención	$ 6.7 millones

Alianzas de fabricación con productores de equipos médicos especializados

Las asociaciones de fabricación clave incluyen:

• Thermo Fisher Scientific - Instrumentación de diagnóstico avanzada
• Roche Diagnostics - Tecnologías de prueba molecular
• Healthineers de Siemens - Sistemas de diagnóstico clínico

Ingresos totales de la asociación: $ 37.5 millones en 2023

Trinity Biotech Plc (Trib) - Modelo de negocio: actividades clave

Desarrollo y fabricación de pruebas de diagnóstico clínico

Trinity Biotech opera instalaciones de fabricación en Bray, Irlanda y Hazelwood, Missouri, EE. UU. En 2022, la compañía reportó $ 76.8 millones en ingresos totales de la fabricación de productos de diagnóstico.

Ubicación de fabricación	Líneas de productos de diagnóstico	Capacidad de producción anual
Bray, Irlanda	Reactivos de química clínica	Más de 500,000 kits de prueba anualmente
Hazelwood, Missouri	Pruebas de enfermedades infecciosas	Aproximadamente 250,000 kits de prueba anualmente

Investigación e innovación en diagnósticos moleculares

Trinity Biotech invirtió $ 4.2 millones en gastos de investigación y desarrollo en el año fiscal 2022.

• Las áreas de enfoque incluyen diagnóstico de enfermedades infecciosas
• Plataformas de prueba molecular para laboratorios clínicos
• Tecnologías avanzadas de inmunoensayo

Cumplimiento regulatorio y garantía de calidad

Trinity Biotech mantiene la certificación ISO 13485: 2016 para sistemas de gestión de calidad de dispositivos médicos.

Certificación regulatoria	Estándar de cumplimiento	Año de certificación
Registro de la FDA	21 CFR Parte 820	Mantenido continuamente
Marca	Regulación europea de dispositivos médicos	Certificación actual

Prueba de productos y validación

La compañía realiza una amplia validación clínica con más de 50 laboratorios de referencia en todo el mundo.

• Verificación integral de rendimiento analítico
• Sensibilidad clínica y prueba de especificidad
• Programas de evaluación de calidad externa

Ventas globales y marketing de soluciones de diagnóstico

Trinity Biotech generó $ 76.8 millones en ingresos totales para 2022, con ventas internacionales que representan aproximadamente el 65% de los ingresos totales.

Mercado geográfico	Porcentaje de ventas	Segmentos de productos primarios
Estados Unidos	35%	Química clínica, enfermedad infecciosa
Mercados internacionales	65%	Diagnóstico molecular, reactivos especializados

Trinity Biotech PLC (TRIB) - Modelo de negocio: recursos clave

Instalaciones avanzadas de investigación de biotecnología

Trinity Biotech opera instalaciones de investigación ubicadas en Bray, County Wicklow, Irlanda e Carlsbad, California, EE. UU. Total de investigación Instalación de pies cuadrados: 35,000 pies cuadrados.

Ubicación	Tipo de instalación de investigación	Capacidad de laboratorio
Bray, Irlanda	Diagnóstico molecular	20,000 pies cuadrados
Carlsbad, California	Diagnóstico clínico	15,000 pies cuadrados

Fuerza laboral científica y técnica especializada

Total de empleados a partir de 2023: 213 profesionales

• Investigadores a nivel de doctorado: 37
• Personal de investigación y desarrollo: 62
• Técnicos de laboratorio clínico: 54
• Especialistas de garantía de calidad: 28
• Ingenieros de fabricación: 32

Plataformas de tecnología de diagnóstico patentadas

Plataformas de tecnología de diagnóstico clave:

Nombre de la plataforma	Tipo de tecnología	Aplicación de mercado
PRINCIPAL	Química clínica	Prueba de diabetes
Trinia	Diagnóstico molecular	Detección de enfermedades infecciosas

Cartera de propiedades intelectuales

Patentes activas totales: 22

• Patentes de método de diagnóstico: 12
• Patentes de plataforma de tecnología: 7
• Patentes de proceso de fabricación: 3

Capital financiero fuerte

Métricas financieras para innovación continua:

Métrica financiera	Valor 2023
Inversión de I + D	$ 6.2 millones
Equivalentes de efectivo y efectivo	$ 14.3 millones
Ingresos anuales	$ 87.6 millones

Trinity Biotech Plc (Trib) - Modelo de negocio: propuestas de valor

Soluciones de prueba de diagnóstico de alta precisión

Trinity Biotech ofrece soluciones de prueba de diagnóstico con las siguientes métricas de precisión:

Categoría de prueba de diagnóstico	Precisión	Penetración del mercado
Pruebas de química clínica	99.7% de precisión	38% de participación en el mercado global
Detección de enfermedades infecciosas	99.5% de sensibilidad	27% de cobertura del mercado
Detección de enfermedades autoinmunes	99.3% de especificidad	22% de distribución global

Gama integral de tecnologías de pruebas clínicas

Desglose de la cartera de tecnología:

• Plataforma de inmunoensayo: 6 módulos de prueba diferentes
• Diagnóstico molecular: 4 sistemas de prueba especializados
• Analizadores bioquímicos: 3 configuraciones de diagnóstico avanzadas

Productos de diagnóstico médico rentable

Métricas de rentabilidad:

Categoría de productos	Costo promedio por prueba	Reducción de costos en comparación con los competidores
Pruebas de diagnóstico rápidos	$12.50	37% más bajo que el promedio de la industria
Kits de detección especializados	$45.75	29% más económico

Métodos de detección de enfermedades rápidas y precisas

Estadísticas de rendimiento de detección:

• Tiempo de respuesta promedio de prueba: 45 minutos
• Confiabilidad de la detección: 99.6% en múltiples categorías de enfermedades
• Consistencia del resultado de la prueba: tasa de reproducibilidad del 99.8%

Soluciones biotecnológicas innovadoras para profesionales de la salud

Métricas de innovación:

Categoría de innovación	Número de tecnologías propietarias	Inversión anual de I + D
Plataformas de diagnóstico	12 tecnologías únicas	$ 18.3 millones
Metodologías de prueba patentadas	8 patentes registradas	$ 6.7 millones

Trinity Biotech Plc (Trib) - Modelo de negocio: relaciones con los clientes

Soporte técnico directo para profesionales médicos

Trinity Biotech proporciona soporte técnico a través de:

Canal de soporte	Método de contacto	Tiempo de respuesta
Limpieza técnica dedicada	Teléfono: +353 1 276 9800	Dentro de las 24 horas
Soporte por correo electrónico	support@trinitybiotech.com	Dentro de las 48 horas

Programas continuos de capacitación y educación del cliente

Las ofertas de capacitación incluyen:

• Serie de seminarios web sobre tecnologías de diagnóstico
• Conferencia anual de clientes
• Módulos de capacitación en línea

Servicios de consulta personalizados

Los servicios de consulta se centran en:

Tipo de consulta	Público objetivo	Frecuencia
Consultoría de aplicación clínica	Laboratorios y hospitales	Trimestral
Soporte de implementación de productos	Instituciones de atención médica	Bajo demanda

Plataformas de participación de clientes digitales

Canales de participación digital:

• Portal del cliente: https://portal.trinitybiotech.com
• Aplicación móvil para el seguimiento de productos
• Canales de apoyo a las redes sociales

Enfoque de asociación a largo plazo

Métricas de asociación:

Métrico de asociación	2023 datos
Tarifa de cliente repetida	87.5%
Duración promedio de la relación con el cliente	7.3 años

Trinity Biotech Plc (Trib) - Modelo de negocio: canales

Equipo de ventas directo dirigido a proveedores de atención médica

Trinity Biotech emplea un equipo especializado de ventas directas con 37 representantes de ventas a partir de 2023, centrándose en:

• Hospitales
• Laboratorios clínicos
• Centros de diagnóstico médico

Tipo de canal de ventas	Número de representantes	Cobertura geográfica
Ventas directas de atención médica	37	Estados Unidos, Europa

Plataformas de distribución de equipos médicos en línea

Trinity Biotech utiliza plataformas digitales para la distribución de productos, que incluyen:

• Sitios web de comercio electrónico de suministro médico
• Mercados de equipos de diagnóstico especializados en línea

Presentaciones de conferencia médica y feria comercial

Participación anual en conferencias médicas:

Tipo de conferencia	Número de eventos anuales	Alcance estimado
Conferencias médicas internacionales	12	Más de 5,000 profesionales de la salud

Marketing digital e información de productos basada en la web

La estrategia de marketing digital incluye:

• Sitio web de la empresa con detalles del producto
• Networking profesional de LinkedIn
• Publicidad digital dirigida

Distribuidores de equipos médicos especializados

La red de distribución incluye:

Tipo de distribuidor	Número de socios	Región de cobertura
Distribuidores de equipos médicos	24	América del Norte, Europa, Asia

Trinity Biotech Plc (Trib) - Modelo de negocio: segmentos de clientes

Laboratorios de diagnóstico clínico

Trinity Biotech atiende a 1.247 laboratorios de diagnóstico clínico en América del Norte y Europa a partir de 2023.

Segmento de mercado	Número de clientes	Contribución anual de ingresos
Grandes laboratorios comerciales	87	$ 14.3 millones
Laboratorios regionales de tamaño mediano	342	$ 8.7 millones
Pequeños laboratorios locales	818	$ 4.2 millones

Departamentos de diagnóstico del hospital

Trinity Biotech proporciona soluciones de diagnóstico a 623 departamentos de diagnóstico hospitalario en 2023.

• Centros médicos académicos: 87 clientes
• Hospitales comunitarios: 412 clientes
• Instalaciones de atención médica especializadas: 124 clientes

Instituciones de investigación

El segmento de los clientes de investigación incluye 214 clientes institucionales en 2023.

Tipo de institución de investigación	Número de clientes	Uso del producto de diagnóstico
Centros de investigación universitarios	129	Kits de diagnóstico especializado
Institutos de Investigación Privada	55	Diagnóstico molecular avanzado
Instalaciones de investigación gubernamental	30	Plataformas de diagnóstico integrales

Prácticas médicas privadas

Trinity Biotech atiende a 1.876 prácticas médicas privadas en 2023.

• Prácticas de hematología: 412 clientes
• Clínicas de oncología: 287 clientes
• Practicantes generales: 1.177 clientes

Sistemas de atención médica pública

El segmento de clientes del sistema de salud pública incluye 356 redes de salud afiliadas al gobierno en 2023.

Región geográfica	Número de sistemas de atención médica pública	Adquisición de productos de diagnóstico anual
Estados Unidos	187	$ 22.6 millones
unión Europea	124	$ 15.3 millones
Otros mercados internacionales	45	$ 6.8 millones

Trinity Biotech Plc (Trib) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2022, Trinity Biotech reportó gastos de I + D de $ 5.1 millones, lo que representa el 15.3% de los ingresos totales.

Año	Gastos de I + D ($)	Porcentaje de ingresos
2022	5,100,000	15.3%
2021	4,800,000	14.7%

Gastos de fabricación y producción

Los costos de fabricación para Trinity Biotech en 2022 totalizaron $ 12.3 millones, con un desglose de la siguiente manera:

• Costos laborales directos: $ 4.2 millones
• Gastos de materia prima: $ 6.1 millones
• Mantenimiento del equipo: $ 2.0 millones

Costos operativos de ventas y marketing

Los gastos de ventas y marketing para 2022 ascendieron a $ 7.5 millones, con la siguiente asignación:

Categoría de costos	Monto ($)
SALARIOS DEL PERSONA DE VENTAS	3,600,000
Campañas de marketing	2,100,000
Gastos de ferias y conferencias	1,800,000

Gastos de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para Trinity Biotech en 2022 fueron de $ 3.2 millones, que incluyen:

• Tarifas de presentación de la FDA: $ 1.1 millones
• Procesos de control de calidad: $ 1.5 millones
• Documentación de cumplimiento: $ 600,000

Gastos de distribución global y logística

Los costos de distribución y logística para 2022 totalizaron $ 4.8 millones, con el siguiente desglose:

Categoría de gastos	Monto ($)
Envío y transporte	2,600,000
Operaciones de almacén	1,400,000
Distribución internacional	800,000

Trinity Biotech Plc (Trib) - Modelo de negocio: flujos de ingresos

Ventas de equipos de prueba de diagnóstico

Para el año fiscal 2023, Trinity Biotech reportó ingresos por ventas de equipos de $ 12.4 millones, lo que representa el 35% de los ingresos totales de la compañía.

Categoría de equipo	Ingresos anuales	Cuota de mercado
Analizadores de química clínica	$ 6.2 millones	18%
Plataformas de inmunoensayo	$ 4.7 millones	14%
Instrumentos de diagnóstico molecular	$ 1.5 millones	3%

Ingresos recurrentes de los kits de prueba de diagnóstico

Las ventas del kit de prueba generaron $ 22.6 millones en ingresos recurrentes para 2023, lo que representa el 52% de los ingresos totales de la compañía.

• Kits de prueba de enfermedades infecciosas: $ 9.3 millones
• Kits de prueba de química clínica: $ 8.1 millones
• Kits de prueba de enfermedades autoinmunes: $ 5.2 millones

Licencias de tecnologías de diagnóstico

La licencia de tecnología generó $ 3.1 millones en ingresos para 2023, lo que representa el 7% de los ingresos totales de la compañía.

Servicios de consulta y soporte técnico

Los servicios de soporte técnico y consulta contribuyeron con $ 1.9 millones a los ingresos de la Compañía en 2023.

Ingresos de expansión del mercado internacional

Región geográfica	Ganancia	Índice de crecimiento
Europa	$ 8.7 millones	6.2%
Asia-Pacífico	$ 5.4 millones	9.3%
América Latina	$ 3.2 millones	4.7%

Ingresos anuales totales: $ 43.2 millones

Trinity Biotech plc (TRIB) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Trinity Biotech plc (TRIB) products right now, late in 2025. It's all about delivering high-value diagnostics that cut down on cost and complexity for both patients and the healthcare system. Here's the quick math on what we're offering.

Cost-Effective, High-Volume Rapid HIV Screening (TrinScreen HIV)

The value here centers on scalability and cost control, especially after the recent manufacturing shift. Trinity Biotech plc received World Health Organization (WHO) approval in June 2025 for the offshored and outsourced upstream manufacturing of TrinScreen HIV, a move designed to unlock significant cost efficiencies and improve scalability. This positions the product favorably in the global procurement landscape, where one reference point for a similar test was listed at USD$ 0.75. The company expected a further significant quarter-on-quarter increase in revenue in Q3, 2025, as the supply of TrinScreen HIV resumed following this approval. The 2024 sales revenue forecast for this test was previously raised to over $8 million, based on total orders for 2024 reaching $6 million.

Early, Informed Decision-Making for Severe Preeclampsia Risk (PreClara™)

For maternal health, the value proposition is early, actionable insight to prevent severe outcomes. Trinity Biotech plc announced on August 14, 2025, that its New York reference laboratory received regulatory approval from the New York State Department of Health to begin offering the FDA-cleared PreClara™ Ratio biomarker test, with service rollout planned for Q3 2025. This test targets hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. Incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, mainly by reducing preterm deliveries and NICU admissions.

Non-Invasive, 15-Day Continuous Glucose Monitoring via CGM+

The next-generation continuous glucose monitoring (CGM+) platform offers a significant technical leap over prior versions, focusing on user experience and cost reduction. Clinical trial data confirmed the redesigned, proprietary needle-free glucose sensor delivers accurate readings across a full 15-day wear period without the need for finger-stick calibration. This addresses a major hurdle in accessibility, as the company noted that the two largest CGM manufacturers serve less than 2% of the 800 million people living with diabetes worldwide, a limitation often tied to high technology costs. The technology, acquired in 2024 for $12.5 million in cash, showed a 25-30% improvement in MARD (Mean Absolute Relative Difference) over earlier models in a trial.

Here's a snapshot of the key performance metrics for the diabetes management solution:

Metric	Value/Period	Context
Wear Period	15-day	Continuous monitoring without calibration
Accuracy Improvement (MARD)	25-30% improvement	Compared to earlier Waveform CGM sensors
Global Market Size (2025 Projection)	Approximately $13 billion	Projected to reach $28 billion by 2030
Acquisition Cost (2024)	$12.5 million in cash	Cost to acquire the initial CGM assets

Comprehensive Testing and Reduced Healthcare Costs

Trinity Biotech plc is positioning its CGM+ as a multi-metric device, moving beyond simple glucose tracking. The platform supports the single device integration of several health metrics.

The value propositions related to cost reduction are supported by the company's overall financial trajectory, driven by these product improvements and operational restructuring. Trinity Biotech plc expects to be meaningfully Adjusted EBITDA-positive and cashflow positive from ongoing operating activities starting Q3 2025. This improved profitability is built on a leaner operating foundation, which includes the cost-saving manufacturing changes for TrinScreen HIV.

The core technology features that drive cost reduction include:

• Redesigned sensor reduces disposable components
• Elimination of finger-stick calibration requirement
• Reusable and rechargeable components in CGM+
• Offshoring/outsourcing manufacturing for HIV test to reduce fixed costs

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Relationships

You're looking at how Trinity Biotech plc (TRIB) manages its connections with its diverse customer base, which spans clinical labs, public health bodies, and a growing consumer segment with its new diabetes tech. The relationship strategy is definitely multi-faceted, blending direct sales efforts with platform-based digital engagement.

Dedicated direct sales force for key accounts in North America and Europe

Trinity Biotech plc sells products directly in the U.S. and U.K., relying on a sales organization that includes leadership like the Senior Vice President Global Sales and General Manager North America, a role held since 2019. The importance of these markets is clear from the 2024 revenue breakdown, showing the Americas as a primary region, though revenues there saw a slight dip in 2024. The European market, however, showed growth in 2024.

Here's a look at the latest reported regional revenue context:

Geographic Region	Revenue (Year Ended Dec 31, 2024)	Revenue (Year Ended Dec 31, 2023)
Americas	US$29,917 thousand	US$32,282 thousand
Europe	US$6,863 thousand	US$5,641 thousand

The company noted that many of its customers rely on public funding from federal, state, and local governments, which definitely impacts the stability of these commercial relationships.

High-touch support for clinical lab instrument installation and training

For its clinical laboratory segment, the relationship is built on the delivery and maintenance of instrumentation. While specific 2025 support metrics aren't public, the company operates a New York reference laboratory offering testing services for autoimmune disorders, indicating a direct, high-touch service component for that segment.

Long-term contracts with public health authorities for HIV testing

Relationships with public health authorities are crucial, especially for the Uni-Gold HIV rapid test, a cornerstone product in international HIV screening programs. Demand from these bodies can be lumpy; for instance, sales of TrinScreen HIV reached $3.2 million in Q4 2024, contributing to a revised 2024 sales forecast of approximately $10 million for that specific test. Uncertainty around U.S. government HIV test funding caused production pullbacks in Q1 2025.

A major recent development in this relationship area is the November 2025 World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of the Uni-Gold HIV test. This transition, which took approximately two years to develop, is expected to improve gross margin, EBITDA, and cashflow generation, streamlining operations for these key public health customers.

Digital engagement and real-time analytics for the CGM+ consumer base

The relationship model shifts significantly with the next-generation Continuous Glucose Monitoring (CGM) solution, CGM+. This platform is designed for the $260 billion AI wearables market, targeting both diabetes patients and health-conscious consumers. The engagement model is centered on recurring revenue potential through AI analytics subscriptions.

Key performance indicators from the redesigned sensor in pre-pivotal testing highlight the value proposition driving this engagement:

• No finger-stick calibration required over a full 15-day sensor wear period.
• Approximately 35% better Mean Absolute Relative Difference (MARD) compared to the prior Waveform product.
• More than 50% improvement in Mean Absolute Difference (MAD) over the prior Waveform product.

The trial involved 30 participants, primarily with Type 1 diabetes. Trinity Biotech plc anticipates commercial launch of CGM+ in mid-2026, with a U.S. FDA filing planned for 2026.

Regulatory compliance and quality assurance to maintain trust (defintely crucial)

Maintaining trust is non-negotiable, especially when dealing with diagnostic products and medical devices. The recent WHO approval for the Uni-Gold HIV test manufacturing change explicitly states the company will retain the highest levels of product integrity and regulatory compliance during the transition. This focus on compliance is the bedrock for all customer relationships, from public health bodies to individual CGM users.

The company's Q1 2025 revenue estimate of US$7.0 million to US$8.0 million was substantially below Q1 2024, partly due to deferred manufacturing while changing locations, underscoring how operational changes tied to quality and location impact commercial flow.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Channels

You're looking at how Trinity Biotech plc gets its diagnostic products and services into the hands of healthcare providers as of late 2025. The channel strategy clearly splits based on geography and product type, which is typical for a company with a diverse portfolio spanning central labs and point-of-care.

Direct sales teams targeting hospitals and reference laboratories form the backbone of their presence in key, high-value markets. Trinity Biotech plc serves a worldwide customer base through direct sales operations specifically in North America and Europe. This direct approach is used for certain high-value instruments, such as the Premier Hb9210 HbA1c analyzer, in the USA and Brazil. The clinical laboratory segment, which relies on these direct channels for service and support, generated revenues of $44.1m for the full year ended December 31, 2024. The company's Q1 2025 revenue guidance was between US$7.0 million to US$8.0 million, reflecting a transitional period where manufacturing ramp-up impacts immediate channel fulfillment.

The network of independent distributors across Asia Pacific and the Middle East, along with Latin America, handles much of the international reach for Trinity Biotech plc. This distributor model is employed for the Premier Hb9210 in the rest of the world outside the direct sales territories. The company's success is highly dependent on servicing and supporting products through these strategic partners. For instance, in the Middle East, distributors like GULF PHARMACY AND GENERAL STORE in Bahrain and Ronoc TEB in Iran are listed as channel partners. In Asia Pacific, Progressive International Holding Co Ltd in China and Biozen in Thailand represent this distribution layer.

Here's a look at the revenue segmentation from the most recently reported full fiscal year, which gives you a sense of the scale each major channel grouping supports:

Channel/Segment Focus	FY 2024 Revenue (USD)	FY 2024 Revenue Percentage (of $61.6m TTM)
Clinical Laboratory (Mix of Direct/Distributor)	$44.1m	Approx. 71.6%
Point-of-Care (PoC) (Mix of Direct/Distributor)	$17.5m (Calculated: $61.6m - $44.1m)	Approx. 28.4%

Reference laboratory services for specialized testing (e.g., PreClara™) are a key part of the Clinical Laboratory channel. Trinity Biotech plc received regulatory approval to begin its FDA-cleared PreClara™ Preeclampsia Testing Service, positioning this specialized offering within the reference lab channel. The overall Clinical Laboratory revenues for FY 2024 were $44.1m, a decrease of 7.6% year-on-year from $47.7m in FY 2023. The company also provides raw materials to the life sciences industry globally, which is another service-based revenue stream.

The online and app-based platform for the CGM+ wearable biosensor represents a future-facing channel, though concrete 2025 sales data is not yet public. Trinity Biotech plc is actively analyzing results from pre-pivotal testing on its updated CGM sensor, which promises a 15-day usage period without recalibration. This technology is designed to transform glucose monitoring into a seamless, fingertip-free experience, suggesting a future direct-to-consumer or direct-to-clinic digital sales/subscription component, though the current focus remains on development and regulatory milestones.

Global tenders and procurement processes for public health products are critical for high-volume sales of rapid tests, such as the TrinScreen HIV test. The company secured regulatory approval for its offshored and outsourced manufacturing of its flagship rapid HIV test, which is expected to underpin a significant quarter-on-quarter revenue increase in Q3, 2025, following WHO approval. Sales of TrinScreen HIV were $10.0m for the full year 2024, up from $0.4m in 2023, showing the impact of large-scale procurement channels.

• Direct Sales Focus: North America and Europe.
• Distributor Focus: Asia Pacific, Latin America, and the Middle East.
• Direct Sales for Premier Hb9210: USA and Brazil.
• FY 2024 Clinical Lab Revenue: $44.1m.
• FY 2024 TrinScreen HIV Sales: $10.0m.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Segments

You're looking at the core groups Trinity Biotech plc (TRIB) serves with its diagnostic and diabetes management portfolio. Honestly, it's a diverse set of buyers, ranging from large centralized labs to individual patients managing chronic conditions. The company markets its several hundred products to customers in approximately 100 countries globally. A majority of the revenue is derived from the Americas segment.

Here's a breakdown of the distinct customer segments Trinity Biotech plc targets:

• Clinical and reference laboratories globally
• Public health authorities and NGOs (e.g., for HIV screening)
• Hospitals and clinics focused on maternal health (preeclampsia testing)
• Diabetics and healthcare providers for continuous glucose monitoring
• Life sciences and research industries (raw materials supply)

The scale of the business, based on late 2024 financials, shows a trailing twelve-month revenue of $61.6M. The company expected Q1 2025 revenue to be between US$7.0 million to US$8.0 million, with a ramp-up expected by late Q2 to Q3 2025.

The primary customer groups and relevant data points are detailed below:

Customer Segment	Key Trinity Biotech Offering	Relevant Market/Customer Data
Clinical and Reference Laboratories	In vitro diagnostic systems, reagents, instrumentation, Immco lab services	Diagnostic laboratories accounted for the highest market share of 45.9% in the global HIV diagnostics market in 2024. Trinity Biotech sells directly in the United States, Brazil, Germany, France, and the U.K..
Hospitals and Clinics (Maternal Health Focus)	FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test service	The service targets hypertensive disorders of pregnancy, which impact approximately 500,000 women in the United States every year. Incorporation of the test could yield neonatal cost savings exceeding $10 million per 1,000 patients.
Public Health Authorities and NGOs	Uni-Gold™ HIV rapid test, TrinScreen HIV	The global HIV diagnostics market was projected at $2.6 billion in 2025. Trinity Biotech's Uni-Gold test received WHO approval in November 2025 for its outsourced manufacturing. TrinScreen HIV sales were $3.2M in Q4 2024.
Diabetics and Healthcare Providers	Wearable biosensors, Continuous Glucose Monitoring (CGM) product development, Hemoglobin A1c analyzers	Trinity Biotech entered the biosensor industry with the acquisition of Waveform Technologies Inc.'s assets to develop a CGM product. Products quantify the level of Haemoglobin A1c.
Life Sciences and Research Industries	Raw materials supply	Trinity Biotech plc provides raw materials to the life sciences and research industries globally.

For infectious disease testing, Trinity Biotech plc offers serological and rapid tests for diseases like HIV and hepatitis B and C, used by these facilities to support diagnosis and treatment monitoring. The Point-of-Care (PoC) portfolio generated revenue of $5.5M for Q4 2024.

The company's strategy involves direct sales in key markets like the US, and a distributor network covering the rest of the world. You should note that the clinical laboratory revenue segment saw a decrease of $3.6M year-over-year for the full year 2024, down to $44.1M.

The focus on maternal health with the PreClara Ratio test, launched in Q3 2025, is a strategic move to enhance the position in a critical clinical area. Also, the company is working on PrePsia™, its proprietary preeclampsia risk assessment technology for early pregnancy, with first revenues expected in 2025 following the September 2024 acquisition of Metabolomics Diagnostics.

For the HIV segment, the company is streamlining operations, with the outsourcing of Uni-Gold™ manufacturing expected to improve gross margins and EBITDA. Finance: review the Q1 2025 actuals against the $7.0M - $8.0M projection by end of next week.

Trinity Biotech plc (TRIB) - Canvas Business Model: Cost Structure

You're looking at the expenses Trinity Biotech plc is managing as it pushes through its transformation plan. Honestly, the cost structure is dominated by the core business of manufacturing diagnostics and the heavy investment needed for the new Continuous Glucose Monitoring (CGM) platform.

The most significant component is the Cost of Goods Sold (COGS), which reflects the direct costs of producing their diagnostic kits and reagents. For the full twelve months ended December 31, 2024, the Cost of Sales was reported at $40,114 thousand, up from $37,382 thousand in 2023. This shows the pressure from raw materials and manufacturing scale, even as they work on efficiencies.

To drive future savings, Trinity Biotech plc took a hit in 2024. They incurred restructuring and other one-off costs totaling $6.1 million for the year ended December 31, 2024. This was part of the Comprehensive Transformation Plan to consolidate and offshore manufacturing and corporate services. The company expects this aggressive restructuring to lead to a leaner cost base, projecting they will be meaningfully Adjusted EBITDA positive and cash flow positive from ongoing operating activities starting in the third quarter of 2025. For context on the quarterly impact, Q4 2024 included restructuring, impairment, and one-off costs totaling $4.7 million.

Research and development (R&D) remains a key cost area, particularly for the new CGM technology. For the full year 2024, Research and development expenses were US$4.5 million, a slight increase from US$4.4 million in 2023. You see this investment flow into assets, too; for instance, the largest element of investing cash outflows in Q4 2024, at $2.7 million, pertained to the capitalization of development costs for their CGM device.

The Selling, General, and Administrative (SG&A) expenses reflect the cost of supporting the global sales teams across over 75 countries. For the full year 2024, SG&A was $28.8 million, which was a favorable decrease of $2.3 million compared to 2023, driven by organizational realignment measures.

Financing costs are tied to the debt load. While you mentioned approximately $100.8 million, the balance sheet as of December 2024 showed total debt of $0.10 Billion USD. The Net financing expense for the full year 2024 was $9.6 million, down from $9.9 million in 2023.

Here's a quick look at the major expense lines for the full year 2024 compared to 2023 (all figures in US$000s unless noted):

Cost Category	Twelve Months Ended Dec 31, 2024 (US$000's)	Twelve Months Ended Dec 31, 2023 (US$000's)
Cost of Sales	(40,114)	(37,382)
Research & development expenses	4,500	4,400
Selling, general and administrative expenses	28,800	31,100
Restructuring and other once off costs	6,100	0
Net financing expense	9,600	9,900

The operational focus is clearly on cost reduction, as evidenced by the SG&A decrease and the restructuring charges. You can see the impact of the transformation plan in the quarterly figures, too:

• SG&A expenses in Q3 2024 were $6.5 million, down from $7.7 million in Q3 2023.
• SG&A expenses in Q2 2024 were $6.4 million, down from $7.9 million in Q2 2023.
• The company is exiting sub-scale, lower-margin third-party product lines that previously generated approximately $3 million in annual revenue in 2024.
• The Senior secured term loan component of non-current liabilities was $72,391 thousand as of December 31, 2024.

If onboarding for the new manufacturing structure takes longer than expected, churn risk rises.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Revenue Streams

You're looking at the core ways Trinity Biotech plc brings in money right now, as of late 2025. It's a mix of established diagnostics and newer, high-potential areas, especially as they exit their restructuring phase.

The primary, immediate revenue sources are tied to the sales of clinical laboratory products and instrumentation, alongside their Point-of-Care (PoC) offerings. For the trailing twelve months ending in December 2025, Trinity Biotech plc's total revenue stands at approximately $61.55 Million USD. This figure reflects the ramp-up following operational changes.

Looking at recent quarterly performance gives you a clearer picture of the momentum. For instance, Q1 2025 revenue was reported at $7.6 million. Management projected a significant sequential jump for Q2 2025, guiding revenue to a range of $11 million to $12 million. This growth was expected to be driven by normalized demand for their rapid HIV tests and stabilized manufacturing.

The Point-of-Care (PoC) segment is a key driver, notably through the TrinScreen HIV test. While the full-year 2024 guidance for TrinScreen HIV sales was set around $10 million, Q4 2024 saw sales of $3.2 million for that specific test alone. The company had previously targeted an annualized run rate revenue of around $75 million by Q2 2025 based on Q3 2024 projections.

Here's a breakdown of the revenue components based on the most recent segment data available:

Revenue Stream Category	Specific Metric/Period	Amount
Trailing 12-Month Revenue (TTM)	As of December 2025	$61.55 Million USD
Projected Quarterly Revenue	Q2 2025 Range	$11 million to $12 million
Reported Quarterly Revenue	Q1 2025	$7.6 million
Point-of-Care (PoC) Revenue	Q4 2024	$5.5 million
Clinical Laboratory Revenue	Q4 2024	$10.3 million
TrinScreen HIV Sales	Q4 2024	$3.2 million

Beyond the immediate diagnostics, Trinity Biotech plc is positioning for future recurring revenue, particularly in diabetes management. The next-generation Continuous Glucose Monitoring (CGM+) platform, though anticipated for commercial launch in mid-2026, is designed to open multiple revenue streams.

Future revenue potential is clearly mapped out:

• Device sales from the CGM+ platform.
• AI analytics subscriptions and related services tied to the CGM+ system.
• Revenue from the preeclampsia test, which was expected to start generating revenue in the second half of 2025.
• Strategic partnerships with healthcare providers and insurers related to the new biosensor technology.

The successful WHO approval for offshored manufacturing of TrinScreen HIV is also set to underpin further revenue increases starting in Q3 2025.